Maggie Cheang
机构: THE INSTITUTE OF CANCER RESEARCH
每年引用次数
引用次数
引用: 40,253
H-指数: 66
I10-指数 : 105
出版物: 231
Breast cancer molecular subtypes and locoregional recurrence
M. C. Cheang , D. Voduc , S. Tyldesley , K. A. Gelmon
Journal of Clinical Oncology 26 510 -510
4
2008
A supervised risk predictor of breast cancer based on biological subtypes
J. Parker , M. Mullins , M. C. Cheang , S. Davies
Journal of Clinical Oncology 26 11008 -11008
8
2008
Molecular and genomic predictors of response to single-agent doxorubicin (ADR) versus single-agent docetaxel (DOC) in primary breast cancer (PBC).
M. Martin , A. Romero , J. Lopez Garcia-Asenjo , M. C. Cheang
Journal of Clinical Oncology 28 502 -502
10
2010
10O_PR Prognostic Significance of Progesterone Receptor-Positive Tumor Cells Within Immunohistochemically-Defined Luminal A Breast Cancer
A Prat , MC Cheang , M Martín , E Carrasco
Annals of Oncology 23
4
2012
Use of immunohistochemical markers can refine prognosis in triple negative breast cancer
Marc Tischkowitz , Jean-Sébastien Brunet , Louis R Bégin , David G Huntsman
BMC Cancer 7 ( 1) 134 -134
551
2007
Stromal mast cells in invasive breast cancer are a marker of favourable prognosis: a study of 4,444 cases
Ashish B. Rajput , Dmitry A. Turbin , Maggie CU Cheang , David K. Voduc
Breast Cancer Research and Treatment 107 ( 2) 249 -257
138
2008
Use of mutation profiles to refine the classification of endometrial carcinomas.
Melissa K McConechy , Jiarui Ding , Maggie CU Cheang , Kimberly C Wiegand
The Journal of Pathology 228 ( 1) 20 -30
205
2012
based PAM50 subtype predictor identifies higher responses and improved survival outcomes in HER2-positive breast cancer in the NOAH study
Aleix Prat , Giampaolo Bianchini , Marlene Thomas , Anton Belousov
Clinical Cancer Research 20 ( 2) 511 -521
225
2014
HER2-enriched subtype and novel molecular subgroups drive aromatase inhibitor resistance and an increased risk of relapse in early ER+/HER2+ breast cancer
Milana A Bergamino , Elena Lopez-Knowles , Gabriele Morani , Holly Tovey
EBioMedicine 83
3
2022
Relationship between ER expression by IHC or mRNA with Ki67 response to aromatase inhibition: a POETIC study
Elena Lopez-Knowles , Simone Detre , Margaret Hills , Eugene F Schuster
Breast Cancer Research 24 ( 1) 61
1
2022
Predicting response and survival in chemotherapy-treated triple-negative breast cancer.
Aleix Prat Aparicio , Ana Lluch Hernández , Joan Albanell Mestres , WT Barry
British Journal of Cancer 111 ( 8) 1532 -1541
132
2014
Molecular Oncology, Markers, Clinical Correlates-Hierarchical Clustering Analysis of Tissue Microarray Immunostaining Data Identifies Prognostically Significant Groups of Breast Carcinoma
Nikita A Makretsov , David G Huntsman , Torsten O Nielsen , Erika Yorida
Clinical Cancer Research 10 ( 18) 6143 -6151
2004
Use of Immunohistochemical Markers can Refine Prognosis in Triple
Marc D Tischkowitz , Jean-Sebastien Brunet , Louis Begin , David G Huntsman
Proc Natl Acad Sci USA 98 ( 19) 10869 -10874
2001
Race, Breast Cancer Subtypes, and Survival in the Carolina Breast Cancer Study
Lisa A Carey , Charles M Perou , Chad A Livasy , Lynn G Dressler
Yearbook of Surgery 2007 304 -305
4,716
2007
Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
Joel S Parker , Michael Mullins , Maggie CU Cheang , Samuel Leung
Journal of Clinical Oncology 41 ( 26) 4192 -4199
1
2023
Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes (Reprinted from vol 27, pg 1160, 2009)
Joel S Parker , Michael Mullins , Maggie CU Cheang , Samuel Leung
JOURNAL OF CLINICAL ONCOLOGY 41 ( 26) 4192 -4199
1
2023
Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials
Jan Hudeček , Leonie Voorwerk , Maartje van Seijen , Iris Nederlof
NPJ breast cancer 6 ( 1) 15 -15
4
2020
Gene expression profiling of breast cancer
Maggie CU Cheang , Matt van de Rijn , Torsten O Nielsen
Annu. Rev. Pathol. Mech. Dis. 3 67 -97
108
2008
RACE, SOUS-TYPES DE CANCER DU SEIN ET SURVIE DANS L'ETUDE CAROLINA BREAST CANCER STUDY
Lisa A Carey , Charles M Perou , Chad A Livasy , Lynn G Dressler
JAMA-français 295 ( 5) a9 -a9
2006
Chemotherapy response and recurrence-free survival in Neoadjuvant breast cancer depends on biomarker profiles: Results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)
Laura J Esserman , Donald A Berry , Maggie CU Cheang , Christina Yau
Breast Cancer Research and Treatment 132 ( 3) 1049 -1062
350
2012